IRWD Stock Earnings Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
IRWD Stock | USD 4.51 0.18 4.16% |
About 55% of Ironwood Pharmaceuticals' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Ironwood Pharmaceuticals suggests that some traders are interested. The current market sentiment, together with Ironwood Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Ironwood Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Ironwood |
IRWD stock results show that Ironwood Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Read at investorplace.com
Ironwood Pharmaceuticals Fundamental Analysis
We analyze Ironwood Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Ironwood Pharmaceuticals is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Ironwood Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ironwood Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Ironwood Pharmaceuticals Related Equities
ASRT | Assertio Therapeutics | 3.53 | ||||
COLL | Collegium Pharmaceutical | 3.07 | ||||
ALKS | Alkermes Plc | 1.01 | ||||
AVDL | Avadel Pharmaceuticals | 0.55 | ||||
PCRX | Pacira BioSciences, | 0.38 | ||||
NBIX | Neurocrine Biosciences | 0.17 | ||||
ANIP | ANI Pharmaceuticals | 0.11 | ||||
AMPH | Amphastar | 0.17 | ||||
ESPR | Esperion Therapeutics | 0.45 | ||||
ITCI | Intracellular | 0.62 |
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |